3 High-Yield Stocks to Buy Hand Over Fist in January

Three high-yield income names are highlighted: Realty Income (O) offers a 5.3% yield, monthly dividends increased annually for 30 years, a 4.2% dividend CAGR over ~30 years, and a portfolio of >15,500 properties; Procter & Gamble (PG) yields 2.8%, reported fiscal Q2 2026 organic sales flat after a 1% volume decline offset by 1% pricing, its stock is ~15% off the 52-week high but remains a Dividend King with 60+ years of raises and a P/E below its five-year average; Pfizer (PFE) yields ~6.7% amid investor concern over patent expirations and a GLP-1 setback, carries a payout ratio slightly above 100% (raising cut risk), but management has moved to bolster its GLP-1 pipeline via acquisition, leaving a material turnaround/upside thesis for long-term investors.

Analysis

Market structure: Winners are high-yield, income-seeking investors and large diversified REITs (O) that can trade on yield vs. cap‑rate dynamics; losers are single‑tenant/smaller retail landlords and premium consumer brands without value alternatives as consumers trade down (pressuring PG’s volume). Pfizer (PFE) is priced for pipeline failure, so any successful M&A or late‑stage approval would reprice biotech sentiment; higher nominal bond yields compress REIT valuations and increase required yields by ~50–150bp before investors rotate back.

Risk assessment: Tail risks include a PFE dividend cut if payout ratio >100% persists (binary within next 2–6 quarters), a 100–200bp jump in 10‑year yields that knocks 10–20% off REIT prices, or a deeper consumer recession that drives PG organic sales down >3% YoY over a year. Short‑term (days–months) volatility will be driven by earnings, FDA/GLP‑1 news, and CPI prints; long‑term (years) outcomes hinge on PFE pipeline replenishment and secular cap‑rate trends for O. Hidden dependency: O’s slow dividend growth masks leverage to cap‑rate movements and tenant credit; PFE’s improvement is highly binary on a handful of clinical readouts or M&A.

Trade implications: Direct plays — modest long in O for income and stability, speculative long in PFE with option protection, and selective accumulation of PG as a Dividend King on deeper dips. Pair trades — long O vs short XRT (retail ETF) to isolate property-credit vs consumer‑demand risk. Options — use a PFE long‑dated collar or buy 18–24 month LEAP calls to capture upside while capping downside from a dividend cut; sell covered calls on PG to enhance yield if held as core.

Contrarian angles: The market likely overprices PFE’s GLP‑1 failure; acquisitions already announced could produce 30–50% upside on successful Phase 2/3 readouts — worth a small, optionality‑focused position. Conversely, O’s apparently “boring” dividend growth understates upside if 10‑year yields fall 50–100bp in 6–12 months (total return 10–20% plausible). The consensus neglects the speed of cap‑rate re‑compression and the binary nature of pharma catalysts — position sizes should reflect those asymmetric outcomes.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in Realty Income (O) for yield; scale to 4–6% if O drops another 5–10% or if 10‑year UST yield falls by 50bp; hedge rate sensitivity by shorting 10‑year futures equal to ~30% of the position DV01 if 10‑yr >4.5%.
• Initiate a 1% speculative long in Pfizer (PFE) via a 24‑month LEAP (buy calls) or a long stock + protective put/collar to limit downside; add another 1–2% only if yield widens to >8% or price falls 20%; cut exposure immediately if management confirms dividend cut or payout ratio remains >100% after next quarter.
• Build a 1–2% core position in Procter & Gamble (PG) using staged buys: add on any pullback that lifts yield above 3.2% or if organic sales decline >2% next quarter; write 1–3 month covered calls to boost income while collecting the 2.8% baseline yield.
• Implement a relative‑value pair: long O (size 2%) vs short XRT (retail ETF, size 2%) to isolate property cashflow resilience vs discretionary retail risk; rebalance if XRT outperforms by >7% or if O underperforms by >7% within 60 days.